
To our knowledge, this is the first report describing a case of vonoprazan-associated QT prolongation newly occurring after initiation of the drug and improving after its discontinuation in a patient concurrently receiving polypharmacy including a drug metabolized by CYP3A4.
Medicine (General), P‐CAB, vonoprazan, R5-920, cardiovascular medicine, long QT syndrome, Images in Clinical Medicine, gastrointestinal medicine
Medicine (General), P‐CAB, vonoprazan, R5-920, cardiovascular medicine, long QT syndrome, Images in Clinical Medicine, gastrointestinal medicine
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 3 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
